NovaBay Pharmaceuticals, Inc. (NBY)

Market Cap	2.89M
Revenue (ttm)	12.14M
Net Income (ttm)	-8.95M
Shares Out	1.88M
EPS (ttm)	-5.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,843
Open	1.45
Previous Close	1.49
Day's Range	1.45 - 1.54
52-Week Range	1.24 - 12.60
Beta	2.77
Analysts	Buy
Price Target	15.30 (+893.51%)
Earnings Date	Mar 30, 2023

About NBY

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne unde...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 26, 2007
• Employees: 29
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: NBY

Financial Performance

In 2021, NBY's revenue was $8.42 million, a decrease of -15.23% compared to the previous year's $9.93 million. Losses were -$6.56 million, -40.58% less than in 2020.

Analyst Forecast

According to 6 analysts, the average rating for NBY stock is "Buy." The 12-month stock price forecast is $15.3, which is an increase of 893.51% from the latest price.

Price Target

$15.3

(893.51% upside)

Analyst Consensus: Buy